Q1 2026 at Lemons 🍋
Squeezed fresh for you: the latest from Lemons.
Hi Everyone,
Welcome back to Lemons in the room, the XR digital-therapy startup reshaping the quality of care in hospitals.
We want to share what’s happening in immersive health and inside our lab of Lemons 🍋
Lemons Journal is where we explore how virtual reality, product design, and neuroscience are redefining healthcare.
The numbers
We beat every target except private sector. Pipeline came from outbound and hospital referrals, not spray-and-pray. Once inside a structure, the natural expansion is 6 to 7 headsets per ward.
Product
Lemo v0.2 shipped. Live in every hospital. Bilingual IT/EN, full spatial audio, rebuilt UIStateManager. Foundation ready for Spanish and German without re-architecting.
Lemo Park in active development.
The XR interaction layer is complete and we are now building out the full experience suite. Pediatric IV procedures using eye-gaze interaction is the first shipping under this line. More in the pipeline. This is not a single product. It is a platform for pediatric care.
Clinical & Regulatory
LEMO IS NOW A CERTIFIED MEDICAL DEVICE.
MDR Class I complete.
Software as a Medical Device, this certification is the regulatory passport that unlocks institutional procurement across Europe, pharma and PSP partnerships, and the German digital therapeutics reimbursement pathway.
We are entering conversations with AIFA and Agenas to position Lemons within the emerging Italian framework for digital therapeutics. A national bill is in progress. When it becomes law, we will be ready: certified, validated, and at the table.
Health Economics, we are pursuing HTA certification alongside an academic partner specialized in health technology assessment. Another fundamental step: it turns clinical outcomes into a procurement budget line. Hospitals that love the product become hospitals that fund it at scale.
Clinical validation, 15 studies in the pipeline, closing the chain from real deployment to peer-reviewed evidence.
Europe
The average hospital sales cycle in Italy is 200 days. The pipeline we have built over the last six months has not yet fully converted, it will.
The numbers today are a fraction of what the next two quarters will show. We are already ahead of that curve, and we are not waiting for Italy to move first.
Spain, active. On May 27 we present at a major international health congress in Barcelona. Meetings already confirmed with the leading pediatric and oncology centers in the country. The groundwork is done.
Germany, relationships established within the healthcare innovation ecosystem. With MDR complete and HTA in progress, we are positioned.
Portugal, France, and broader EU markets are in scope. The regulatory and clinical infrastructure we are building in 2026 is designed from day one for multi-market deployment.
UAE and Dubai, a market we are watching closely. Healthcare innovation is a national priority, procurement cycles are fast, and the appetite for premium digital health solutions is unlike anywhere in Europe. We have early interest and are evaluating the right entry point.
Fundraising
We did not raise this round for the money. We raised it for the people.
The angels we brought in include: our lawyer specialized in public procurement, healthcare regulation, and Italian public tenders; senior figures from leading international pharmaceutical companies; and experienced startup operators and business mentors.
We are now building the advisory layer, a structured group at C-level to accelerate commercial and institutional partnerships. The goal is not just capital. It is leverage.
Next round: Seed VC, valuation target €15+M. Soon.
Q2 priorities
Three, not ten.
Close the open pipeline.
Extend session depth.
Build CS as infrastructure.
Customer Success moves from a relationship function to a data-generating system embedded in each hospital. This is what makes year 2 renewals a natural conversation, not a difficult one.
The frame
We’re not a VR company. We’re a digital therapeutics infrastructure that uses VR because it’s currently the best delivery mechanism available.
The headset is replaceable. What isn’t: the hospital network, the clinical protocol, the regulatory know-how, and the outcomes evidence.
That’s the asset. Everything else is execution.
As always if you have connections to clinical researchers, EU hospitals, or pharma that fits this picture, we want to hear from you.